Abiraterone & Enzalutamide Up Adverse CV & Metabolic Event Risks
For men with advanced prostate cancer, receipt of abiraterone or enzalutamide is linked with an increased risk for major metabolic or cardiovascular adverse events, according to a study published in the Journal of the National...
Read More